Arcus Biosciences, Inc. (RCUS) 

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Show less

Over the last 12 months, insiders at Arcus Biosciences, Inc. have bought $320M and sold $2.75M worth of Arcus Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Arcus Biosciences, Inc. have bought $140.4M and sold $2.99M worth of stock each year.

Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $1.6B.

The last purchase of 15,238,095 shares for transaction amount of $320M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑01‑29.